Vect-Horus, a France-based biotechnology company specialising in blood-brain barrier (BBB) technologies, has entered a strategic collaboration with South Korea’s OliX Pharmaceuticals (KOSDAQ: 226950) to advance RNA interference (RNAi) therapeutics for central nervous system (CNS) disorders, as reported by GlobeNewswire.

The agreement, structured as a Material Transfer and Evaluation Agreement (MTEA), will assess the efficiency of CNS delivery of siRNA conjugates by measuring gene silencing activity and biodistribution across major organs.

The partnership integrates Vect-Horus’ VECTrans® BBB shuttle platform with OliX’s proprietary siRNA technology.

Alexandre Tokay, CEO of Vect-Horus, said: “We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus’ leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with Pharma and Biotech companies like OliX. This partnership has the potential to accelerate the development of innovative treatments and bring renewed hope to patients worldwide, and we are looking forward to a strong collaboration with OliX.”

OliX CEO Dong Ki Lee added: “We consider this collaboration a pivotal milestone as OliX evolves from a siRNA-focused company into a platform-based biopharmaceutical company with expanded delivery capabilities and therapeutic scope. By proactively evaluating a BBB shuttle technology that has already been validated by global pharmaceutical leaders, we aim to enhance the probability of successful CNS drug development while creating long-term value through future collaboration opportunities.”

The collaboration represents a strategic step in OliX’s “OliX 2.0 Roadmap,” targeting CNS therapeutics as a next growth driver following its focus on metabolic and obesity-related therapies.

VECTrans® has already been validated globally through licensing agreements with companies including Novo Nordisk, Ionis Pharmaceuticals, and RadioMedix, reinforcing its position as a core enabling technology for CNS drug delivery.

Explore the full report on how BBB shuttle platforms are reshaping CNS therapeutic development.